Weight loss drug company Kailera Therapeutics (KLRA.US) plans to price its IPO at $14-16 per share and aims to debut on the Nasdaq on Friday.

Biotechnology company Kailera Therapeutics (KLRA.US), which focuses on developing injectable and oral GLP-1 class drugs for the treatment of obesity, announced its initial public offering (IPO) terms on Monday. The Massachusetts-based company plans to raise $500 million by issuing 33 million shares of stock at a price range of $14 to $16 per share. Some shareholders intend to subscribe to $225 million worth of shares in this offering, accounting for 45% of the total transaction. According to the plan, Kailera is expected to complete the final pricing on Thursday evening (April 16) and begin trading on the Nasdaq Stock Exchange the following day. Currently, Kailera is advancing four clinical-stage candidate drugs for obesity, utilizing various mechanisms and routes of administration based on glucagon-like peptide-1 (GLP-1). Its core candidate drug ribupatide (also known as KAI-9531) is currently conducting global Phase III clinical trials, which is a once-weekly injectable GLP-1/glucose-dependent insulinotropic polypeptide agonist peptide. The company is expanding its ribupatide product line by developing a once-daily oral tablet formulation - oral ribupatide, based on the same peptide segment as injectable ribupatide. Notably, Kailera's core assets are deeply tied to its Chinese background, with all of its pipeline products originating from a strategic partnership with Chinese pharmaceutical giant Jiangsu Hengrui Pharmaceuticals. In 2024, the company obtained global development and commercialization rights outside of Greater China for four GLP-1 and related targets candidate drugs from Jiangsu Hengrui Pharmaceuticals. Of the current pipeline, the once-weekly GLP-1/GIP receptor dual agonist ribupatide as the core candidate drug, with its global Phase III clinical trial progress attracting attention as a strong potential competitor to Novo Nordisk A/S Sponsored ADR Class B Wegovy and Eli Lilly's Zepbound. In terms of formulation expansion, the company is also advancing the development of once-daily oral tablet formulation based on the same peptide segment, entering the global multi-billion dollar obesity market with a more convenient administration method, forming a dual-line product layout of injectable and oral administration. In terms of financial performance and capital path, Kailera has demonstrated strong fundraising capabilities and expansion ambitions. In 2025, the company completed a Series B financing of up to $600 million, setting one of the highest records in the biotechnology industry that year. Although the company still had a substantial cash reserve of $546 million by the end of 2025, its net loss for the full year of 2025 reached $149 million due to the expensive late-stage clinical development of new drugs. The listing on Nasdaq marks a crucial turning point for the company from its early stage to commercialization. Kailera Therapeutics was founded in 2024 and plans to list on Nasdaq under the ticker symbol KLRA. J.P. Morgan, Jefferies Financial Group Inc., Leerink Partners, Credit Suisse, and Evercore ISI are acting as joint bookrunners for this transaction.